🔗 Share this article

A daily weight loss tablet could assist people reduce their weight by up to a fifth, as per a trial that might pave the way for millions more individuals to lose weight.

The Way the Medication Works

This medication, known as orforglipron, focuses on the same GLP-1 pathways as weight loss injections like tirzepatide and semaglutide. During research of over 3,000 participants, one in five people who took the once-a-day tablet for 72 weeks shed at least one-fifth of their body weight.

Weight loss jabs are revolutionary, but pill versions are seen as a holy grail since they are easier to keep, distribute and administer, and are also projected to be more affordable, providing fresh hope for millions attempting to reduce weight.

The medication is a GLP-1 agonist, a class of drug that helps lowering glucose readings, slows the breakdown of food and can reduce appetite.

Trial Results and Convenience

Slimming results seen in people using the pill is not as stark as those in users using injectable alternatives, but specialists believe the oral form is more accessible and user-friendly compared with injections.

Orforglipron is not yet approved by the US Food and Drug Administration or regulators in other countries. The manufacturer stated it expects substantial demand once the oral treatment is launched.

During the trial, the 3,127 patients were split into cohorts taking the medication pills of different dosages, while some took a dummy pill, for the trial period.

All of the patients were diagnosed with obesity, indicating they had a BMI reading of 30 or over, but they were free from diabetes. Patients from multiple nations took part in the research.

Key Outcomes

Scientists found that after 72 weeks users on the smallest amount reduced an average of nearly 8% of their body weight. Those taking the highest dose lost an average of over 11% of their body weight.

In patients taking the highest doses, 54.6% had a decrease of at least 10% of body weight, 36% had a loss of 15% or greater, and 18.4% had a drop of 20% or higher.

The team said other health metrics additionally improved in people using the medication, including improved blood pressure, a reduced waist size and a decrease in LDL levels.

Frequent adverse reactions were stomach-related, which were said to be mild to moderate.

“In adults with excess weight, 72-week treatment with orforglipron led to notable reductions in weight than placebo,” researchers wrote.

Future Impact

Health experts have hailed weight loss treatments as game-changing. However injections come with additional work for medical systems, so tablet forms might benefit many additional individuals aiming to lose weight.

Separate research shows slimming injections may be effective on children starting from six who are obese or are diagnosed with type 2 diabetes. But, stomach problems were reported more frequently among children using the drugs.

They said that extended follow-up periods in future studies and additional practical analysis were “essential to determine the lasting effects.”